Takeda Pharmaceutical (TAK) Liabilities and Shareholders Equity (2018 - 2026)

Takeda Pharmaceutical has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $98.3 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 1.53% year-over-year to $98.3 billion in Q2 2026; TTM through Jun 2026 was $395.5 billion, a 2.13% increase from a year earlier, with the FY2026 full-year figure at $98.9 billion, up 5.74% from the prior year.
• Liabilities and Shareholders Equity was $98.3 billion for Q2 2026 at Takeda Pharmaceutical, down from $98.9 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $113.4 billion in Q1 2022, with the low at $93.4 billion in Q1 2025.
• Average Liabilities and Shareholders Equity over 5 years is $101.4 billion, with a median of $99.7 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity fell 14.43% in 2022, then increased 5.91% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $95.6 billion in 2022, then advanced by 0.66% to $96.2 billion in 2023, then increased by 3.27% to $99.4 billion in 2024, then increased by 0.76% to $100.1 billion in 2025, then fell by 1.85% to $98.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $98.3 billion (Q2 2026), $98.9 billion (Q1 2026), and $100.1 billion (Q4 2025), per Business Quant data.